Business Description
Agenus Inc
NAICS : 325414
SIC : 2836
ISIN : US00847G7051
Description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.98 | |||||
| Equity-to-Asset | -0.51 | |||||
| Debt-to-Equity | -0.49 | |||||
| Debt-to-EBITDA | -0.54 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -10.25 | |||||
| Beneish M-Score | 2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.1 | |||||
| 3-Year EBITDA Growth Rate | 15 | |||||
| 3-Year EPS without NRI Growth Rate | 12.4 | |||||
| 3-Year FCF Growth Rate | 7.5 | |||||
| 3-Year Book Growth Rate | 26.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 24.02 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.13 | |||||
| 9-Day RSI | 55.18 | |||||
| 14-Day RSI | 47.51 | |||||
| 6-1 Month Momentum % | -28.22 | |||||
| 12-1 Month Momentum % | -65.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.44 | |||||
| Quick Ratio | 0.44 | |||||
| Cash Ratio | 0.3 | |||||
| Days Sales Outstanding | 15.11 | |||||
| Days Payable | 74.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.2 | |||||
| Shareholder Yield % | -89.18 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -52.05 | |||||
| Operating Margin % | -102.43 | |||||
| Net Margin % | -157.22 | |||||
| FCF Margin % | -149.8 | |||||
| ROA % | -66.09 | |||||
| ROIC % | -47.94 | |||||
| ROC (Joel Greenblatt) % | -94.68 | |||||
| ROCE % | -97.12 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.96 | |||||
| EV-to-EBIT | -0.99 | |||||
| EV-to-Forward-EBIT | -0.85 | |||||
| EV-to-EBITDA | -1.08 | |||||
| EV-to-Revenue | 1.01 | |||||
| EV-to-Forward-Revenue | 1.16 | |||||
| EV-to-FCF | -0.67 | |||||
| Price-to-Median-PS-Value | 0.12 | |||||
| Earnings Yield (Greenblatt) % | -101.01 | |||||
| FCF Yield % | -134.69 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers